Another strong quarter for Baxter's specialties
This article was originally published in Clinica
Baxter's third-quarter sales grew 6% to $2,456 million due to another quarter with strong 15% growth in the medical specialties division. With net income up 9%, "Baxter is on track to reach its financial goals for 1995, including earnings growth in the high single digits and operational cash flow of $500 million," says CEO Vernon Loucks.
You may also be interested in...
US FDA considering approach that is similar to, but more stringent than, influenza strain changes, CBER Director Marks says. But how to know what variants need a limited study and which one need a big one will be an ongoing challenge, NIH's Graham notes. As FDA and sponsors gain more experience with tweaking the vaccines to account for new coronavirus variants and strains, the process may be expedited further.
Nina Daily, chief marketing officer at the Professional Beauty Association since July 2018, will succeed Steve Sleeper as executive director at the end of June when Sleeper retires. More cosmetics industry appointments.
New round of orders would give the US all the vaccine it needs from the existing mRNA products, taking pressure off AstraZeneca as it experiences manufacturing challenges and the EU considers export restrictions to ensure it gets enough vaccine.